Core Viewpoint - The article emphasizes the risk of drug-induced kidney damage, highlighting the importance of awareness and monitoring for early signs of kidney injury due to medication use [4][5][6]. Group 1: Drug-Induced Kidney Damage Mechanism - The kidneys receive 20% to 25% of the heart's output, making them directly exposed to drugs in the bloodstream, increasing the risk of damage [5]. - The renal tubules concentrate drugs and their metabolites, raising their levels and the potential for epithelial cell injury [5]. - Elderly individuals and those with pre-existing conditions like diabetes and hypertension are at higher risk due to compromised kidney function [5][6]. Group 2: Early Warning Signs of Kidney Damage - Changes in urine output and characteristics, such as less than 400 milliliters (oliguria) or more than 2500 milliliters (polyuria) in 24 hours, should be monitored [6]. - General symptoms like unexplained fatigue, dizziness, and nausea may indicate kidney issues [6]. - Other symptoms include sudden hypertension and edema, which require regular kidney function monitoring, especially for those on long-term medication [6]. Group 3: Common Medications Associated with Kidney Damage - Cancer treatment drugs, including chemotherapy and targeted therapies, pose significant risks for kidney damage due to their mechanisms and prolonged use [7][8]. - Non-steroidal anti-inflammatory drugs (NSAIDs) can lead to acute kidney injury when used excessively, particularly in combination with other medications [9]. - Diabetes medications like metformin and certain sulfonylureas require careful monitoring in patients with renal impairment to avoid complications [9]. Group 4: Preventive Measures for Kidney Health - Adhering to prescribed medication regimens and not self-adjusting dosages is crucial for preventing kidney damage [10]. - Patients should inform healthcare providers of their medical history, including any kidney issues or other relevant conditions [11]. - Staying hydrated during medication use can help facilitate the excretion of drug metabolites [13]. - Regular monitoring of kidney function and urine tests is essential for those on long-term medications to detect abnormalities early [14]. Group 5: Traditional Chinese Medicine Perspective - Traditional Chinese Medicine views drug-induced kidney damage as "toxic damage to the kidneys," with treatment tailored to individual patient conditions [15]. - Various treatment methods, including herbal remedies and external therapies, are employed to address kidney damage [15]. Conclusion - Early detection and timely intervention are critical in managing drug-induced kidney damage, which is largely preventable and treatable [16].

Core Viewpoint - Green Leaf Pharmaceutical (02186) experienced a stock price increase of over 5% following the release of its interim results, with the current price at HKD 3.53 and a trading volume of HKD 180 million [1] Financial Performance - For the six months ending June 30, 2025, the company reported a revenue of RMB 3.181 billion, representing a year-on-year increase of 3.46% [1] - The profit attributable to the parent company was RMB 313 million, a decrease of 19.33% year-on-year [1] - Earnings per share stood at 8.32 cents [1] Segment Performance - Revenue from the oncology treatment segment increased by 13.5%, reaching RMB 1.295 billion [1] - Revenue from the central nervous system treatment segment grew by 5.4%, amounting to RMB 868 million [1] - Revenue from the cardiovascular treatment segment decreased by 9.2%, totaling RMB 693 million [1] - Revenue from the metabolic treatment segment declined by 7.9%, reaching RMB 180 million [1]

Group 1 - The core viewpoint of the article highlights the recent stock performance of Lepu Biopharma-B, which saw a decline of 5.01% to 8.91 CNY per share, with a trading volume of 308 million CNY [1] - Lepu Biopharma focuses on biopharmaceutical research and development in the oncology treatment field, particularly in targeted therapy and immunotherapy, and has established a comprehensive end-to-end capability in drug discovery, clinical development, CMC, and GMP-compliant production [1] - The company has built a professional sales and marketing team aimed at meeting clinical needs and providing optimized and innovative drug solutions [1] Group 2 - As of the 2024 annual report, Lepu Biopharma reported total operating revenue of 368 million CNY and a net profit of -411 million CNY [2] - A forecast for the mid-2025 performance indicates an expected profit of approximately 24 million CNY, representing a year-on-year increase of 112.18% [3]